Late-onset myoclonic epilepsy in Down syndrome (LOMEDS) as a new clinical marker for Alzheimer's disease: a multicentre, longitudinal, prospective, observational cohort study
Cited in blog · The Lancet Neurology. · 2024
Lage-Martinez A, et al. (2024). Late-onset myoclonic epilepsy in Down syndrome (LOMEDS) as a new clinical marker for Alzheimer's disease: a multicentre, longitudinal, prospective, observational cohort study. *The Lancet Neurology*.
Authors
Lage-Martinez A, et al.
Research lens
Lage-Martinez A, et al. (2024). Late-onset myoclonic epilepsy in Down syndrome (LOMEDS) as a new clinical marker for Alzheimer's disease: a multicentre, longitudinal, prospective, observational cohort study. *The Lancet Neurology*.
- blog
- late-onset-seizures-alzheimers-2026-09-30